Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM.
Prostate. 2012 Feb 1. doi: 10.1002/pros.22499. [Epub ahead of print]
Related citations
A panel of five circulating microRNAs as potential biomarkers for prostate cancer.
Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J.
Prostate. 2012 Feb 1. doi: 10.1002/pros.22495. [Epub ahead of print]
Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA.
Prostate. 2012 Jan 31. doi: 10.1002/pros.22489. [Epub ahead of print]
"Combi-targeting" mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ.
Prostate. 2012 Jan 30. doi: 10.1002/pros.22475. [Epub ahead of print]
Glycoprotein transmembrane nmb: An androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells.
Tsui KH, Chang YL, Feng TH, Chang PL, Juang HH.
Prostate. 2012 Jan 30. doi: 10.1002/pros.22494. [Epub ahead of print]
Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.
Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H.
Prostate. 2012 Jan 30. doi: 10.1002/pros.22493. [Epub ahead of print]
Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines.
Ide H, Lu Y, Yu J, China T, Kumamoto T, Koseki T, Yamaguchi R, Muto S, Horie S.
Prostate. 2012 Jan 30. doi: 10.1002/pros.22492. [Epub ahead of print]
Seven years of experience with high-intensity focused ultrasound for prostate cancer: Advantages and limitations.
Sung HH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.
Prostate. 2012 Jan 17. doi: 10.1002/pros.22491. [Epub ahead of print]
Effect of dual inhibition of apoptosis and autophagy in prostate cancer.
Saleem A, Dvorzhinski D, Santanam U, Mathew R, Bray K, Stein M, White E, Dipaola RS.
Prostate. 2012 Jan 12. doi: 10.1002/pros.22487. [Epub ahead of print]
Frequency and determinants of disagreement and error in gleason scores: A population-based study of prostate cancer.
Goodman M, Ward KC, Osunkoya AO, Datta MW, Luthringer D, Young AN, Marks K, Cohen V, Kennedy JC, Haber MJ, Amin MB.
Prostate. 2012 Jan 6. doi: 10.1002/pros.22484. [Epub ahead of print]
Increased TGF-β1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling.
Miles FL, Tung NS, Aguiar AA, Kurtoglu S, Sikes RA.
Prostate. 2012 Jan 6. doi: 10.1002/pros.22482. [Epub ahead of print]
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.
Terracciano D, Bruzzese D, Ferro M, Mazzarella C, Di Lorenzo G, Altieri V, Mariano A, Macchia V, Di Carlo A.
Prostate. 2012 Jan;72(1):100-7. doi: 10.1002/pros.21411. Epub 2011 Apr 25.
The association between inflammation-related genes and serum androgen levels in men: the prostate, lung, colorectal, and ovarian study.
Meyer TE, Chu LW, Li Q, Yu K, Rosenberg PS, Menashe I, Chokkalingam AP, Quraishi SM, Huang WY, Weiss JM, Kaaks R, Hayes RB, Chanock SJ, Hsing AW.
Prostate. 2012 Jan;72(1):65-71. doi: 10.1002/pros.21407. Epub 2011 Apr 25.
Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.
Komatsu S, Hara N, Ishizaki F, Nishiyama T, Takizawa I, Isahaya E, Kawasaki T, Takahashi K.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22471. [Epub ahead of print]
A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.
Ouzaid I, Yates DR, Hupertan V, Mozer P, Chartier-Kastler E, Haertig A, Bitker MO, Rouprêt M.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22470. [Epub ahead of print]
High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells.
Takeuchi I, Takaha N, Nakamura T, Hongo F, Mikami K, Kamoi K, Okihara K, Kawauchi A, Miki T.
Prostate. 2012 Jul 1;72(10):1124-32. doi: 10.1002/pros.22460. Epub 2011 Dec 27.
Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction.
Najy AJ, Jung YS, Won JJ, Conley-Lacomb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22481. [Epub ahead of print]
Variations in the exome of the LNCaP prostate cancer cell line.
Spans L, Atak ZK, Van Nieuwerburgh F, Deforce D, Lerut E, Aerts S, Claessens F.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22480. [Epub ahead of print]
LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.
Ge D, Gao AC, Zhang Q, Liu S, Xue Y, You Z.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22479. [Epub ahead of print]
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.
Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG.
Prostate. 2011 Dec 27. doi: 10.1002/pros.22478. [Epub ahead of print]
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on